Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
14.72
-0.71 (-4.60%)
At close: Aug 11, 2026, 4:00 PM EDT
14.75
+0.03 (0.20%)
After-hours: Aug 11, 2026, 7:53 PM EDT
Silence Therapeutics Employees
Silence Therapeutics had 88 employees as of December 31, 2025. The number of employees decreased by 28 or -24.14% compared to the previous year.
Employees
88
Change (1Y)
-28
Growth (1Y)
-24.14%
Revenue / Employee
$6,989
Profits / Employee
-$681,284
Market Cap
695.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 88 | -28 | -24.14% |
| Dec 31, 2024 | 116 | 7 | 6.42% |
| Dec 31, 2023 | 109 | -13 | -10.66% |
| Dec 31, 2022 | 122 | 17 | 16.19% |
| Dec 31, 2021 | 105 | 40 | 61.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| REGENXBIO | 371 |
| Phathom Pharmaceuticals | 371 |
| Allogene Therapeutics | 152 |
| BridgeBio Oncology Therapeutics | 106 |
| Crescent Biopharma | 69 |
| CytomX Therapeutics | 69 |
| AgomAb Therapeutics NV | 62 |
SLN News
- 4 hours ago - Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering - Business Wire
- 19 hours ago - Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley - TheFly
- 1 day ago - Silence Therapeutics files to sell $150M in ADS’s - TheFly
- 1 day ago - Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares - Business Wire
- 1 day ago - Silence Therapeutics Transcript: Study result - Transcripts
- 1 day ago - Silence Therapeutics Press release: Study result - Filings
- 1 day ago - Silence Therapeutics Slides: Study result - Filings
- 1 day ago - Silence announces results from Phase 2 SANRECO trial met primary endpoint - TheFly